Results 181 to 190 of about 671,892 (268)

Reduction in Renal Relapse and Preservation of Long‐Term Kidney Function After Lupus Low Disease Activity in Patients With Lupus Nephritis

open access: yesArthritis Care &Research, EarlyView.
Objective Lupus low disease activity state (LLDAS) is a validated treatment target in systemic lupus erythematosus (SLE), but limited studies have explored the role of LLDAS in lupus nephritis (LN). This study aims to investigate the frequency and predictors of LLDAS attainment and its benefit on LN relapse and renal function preservation in patients ...
Chak Kwan Cheung   +6 more
wiley   +1 more source

Histone Phosphorylation in DNA Damage Response. [PDF]

open access: yesInt J Mol Sci
Gong P, Guo Z, Wang S, Gao S, Cao Q.
europepmc   +1 more source

Exploring patients’ profiles associated with the resolution of acute calcium pyrophosphate arthritis treatedwith colchicine and prednisone: post hoc analysis of a randomized controlled trial

open access: yesArthritis Care &Research, Accepted Article.
Objective The objective was to identify factors determining acute arthritis resolution and safety with colchicine and prednisone in acute calcium pyrophosphate (CPP) crystal arthritis. Methods We conducted a post hoc analysis of the COLCHICORT trial, which compared colchicine and prednisone for the treatment of acute CPP crystal arthritis, using a ...
Tristan Pascart   +14 more
wiley   +1 more source

The interconnection between androgen receptor and DNA damage response pathways in prostate cancer. [PDF]

open access: yesCurr Urol
Sands M   +10 more
europepmc   +1 more source

Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Belimumab in Pediatric Patients with Systemic Lupus Erythematosus: A Multicenter, Open‐Label Trial

open access: yesArthritis Care &Research, Accepted Article.
Objective This study aimed to characterize the pharmacokinetics, pharmacodynamics, safety, and exploratory efficacy of subcutaneous belimumab in pediatric patients with active systemic lupus erythematosus (SLE) receiving standard therapy. Methods This single‐arm, multicenter, open‐label trial (GSK study 200908; NCT04179032) used three‐weight‐band ...
Hermine I. Brunner   +14 more
wiley   +1 more source

Post-translational modifications of SOG1 enable dynamic control of plant DNA damage response. [PDF]

open access: yesSci Adv
Bao W   +9 more
europepmc   +1 more source

Role of Prednisone and 25(OH) Vitamin D on Bone Mineral Density and Osteoporosis in Systemic Lupus Erythematosus

open access: yesArthritis Care &Research, Accepted Article.
Objective We evaluated the role of 25‐hydroxy vitamin D, prednisone and other risk factors for bone mineral density (BMD) loss and osteoporosis in systemic lupus erythematosus (SLE). Methods We calculated the association between 25‐hydroxy vitamin D [25(OH)D] levels and other potential risk factors with BMD measures (spine T‐scores) and osteoporosis ...
Nima Madanchi   +4 more
wiley   +1 more source

DNA damage response pathway regulates Nrf2 in response to oxidative stress. [PDF]

open access: yesSci Adv
Jiang XY   +20 more
europepmc   +1 more source

RRP9 Promotes Esophageal Squamous Cell Carcinoma Progression through E2F1 Transcriptional Regulation of CDK1

open access: yesAdvanced Biology, EarlyView.
The study reveals that RRP9 is abnormally highly expressed in ESCC tissues and is closely associated with poor prognosis in patients. Furthermore, it is found that RRP9 promotes ESCC progression through enhancing the E2F1‐mediated transcriptional regulation of CDK1.
Gang He   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy